RAS- Targeted Drug Development

Event Details

September 26th - 28th, 2022 | Boston

Applied BioMath Presence

Presentation: Application of a quantitative systems pharmacology model to support differentiation of ASP2453, a novel KRASG12C inhibitor

Presenter: Diana Marcantonio, PhD, Director of Biology

Presentation Time: Tuesday, September 27th at 1:00pm ET


  • KRASG12C mutations lead to constitutive proliferation signaling and are prevalent across human cancers. Sotorasib, a KRASG12C inhibitor, was recently approved for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer, and several other KRASG12C inhibitors are in clinical trials. 
  • ASP2453 is a novel, highly-potent, and selective inhibitor of KRASG12C. Will ASP2453 show a more favorable clinical response compared to its competitors? 
  • To address this question, we developed a quantitative systems pharmacology (QSP) model linking KRAS signaling to tumor growth. Virtual clinical trial simulations using the QSP model suggest ASP2453 will exhibit superior antitumor efficacy in patients, supporting potential differentiation and critical thinking for clinical trials.